A Prospective Analysis of the Efficacy of Allosync Expand and Autograft Bone Graft in Open Lumbar Spinal Fusion

NCT ID: NCT06415110

Last Updated: 2025-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-05

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the radiographic and clinical outcomes of spinal fusion following use of Allosync Expand and autograft bone graft.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single site, prospective study with patients selected as study subjects from the Investigator's standard patient population who fulfill the Inclusion/Exclusion Criteria and agree to participate in the study. The study surgery is standard of care, with patients identified as requiring surgery prior to enrollment. The study surgery is lumbar posterior fixation with supplemental posterolateral fusion at from 1 to 3 levels. One side of the posterolateral fusion will be Allosync Expand (utilizing the BMA Angel kit to hydrate) and the other side to autograft bone (control).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondylolisthesis, Grade 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allosync Expand

All enrolled patients will received Allosync Expand at 1-3 contiguous levels (L1-S1).

Allosync Expand

Intervention Type DEVICE

Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Allosync Expand

Allosync Expand is used in lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Acceell Family of Products (Accell DBM 100, Accell TBM, A2i, and Accell Connexus)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. At least 22years of age at the time of consent
2. Subject must have a documented diagnosis of spondylolisthesis up to Grade I. and have confirmed back and/or radicular pain with associated spinal stenosis as documented by conditions such as:

1. Instability as defined by \>3mm translation or \>5 degree angulation
2. Osteophyte formation of facet joints or vertebral endplates
3. Subject presents with one or more of the following:

1. Radiculopathy
2. Sensory deficit
3. Motor weakness
4. Reflex changes
4. Subject requires lumbar posterolateral arthrodesis at 1-3 contiguous levels (L1-S1).
5. The number of levels decompressed must equal the number of levels fused.
6. Subject must have been unresponsive to conservative care for at least 3 months prior to fusion surgery.
7. Subject must be willing and able to sign an informed consent document.
8. Subject must be willing and able to return for all follow-up visits, agree to participate in postoperative clinical and radiographic evaluations and comply with the required study regimen.

Exclusion Criteria

1. Subject has had prior lumbar spine fusion surgery at any level.
2. Subject has greater than grade 1 spondylolisthesis of the lumbar spine.
3. Subject is pregnant or nursing or planning to become pregnant during the two years (24 months) following arthrodesis
4. Subject has an active local or systemic infection.
5. Subject is a prisoner
6. Patient has any condition (including malignancy), that in the opinion of the Investigator, would prohibit the patient from complying with and/or completing the protocol
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Research Source

NETWORK

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michigan Orthopaedic Surgeons

Southfield, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Allosync Expand

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evidence For Fusion In Spine With Orthoss®
NCT03853356 ACTIVE_NOT_RECRUITING
Artoss Prospective Spine Registry Outcomes
NCT04439032 ACTIVE_NOT_RECRUITING